Navigation Links
Tom Shaw's NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen

Coach Tom Shaw has Trained the Last 7 Super Bowl MVP's; 94 NFL First Round

Draft Picks; 6 Number 1 Overall NFL Draft Picks and 18 Starting

Quarterbacks in the NFL Last Season

BASKING RIDGE, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Inc., wholly-owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), announced today that SURGEX(TM) is currently being administered as the exclusive post workout nutritional product provided to elite Division I Collegiate Football Athletes training for the NFL Combine at Tom Shaw's Performance Pre-Combine Camp, ( Disney's Wide World of Sports Complex in Orlando, Florida serves as the venue for Coach Tom Shaw's Camp, where NFL dreams become reality for potential NFL Players. Athletes preparing to enter the NFL Draft in April representing teams from the SEC, ACC, Big Ten, Big XII, Big East and Pac-10 are using the SURGEX(TM) product, to aid in their strength and recovery, as part of Coach Tom Shaw's Performance Pre-Combine Camp.

Coach Tom Shaw is proud to offer SURGEX(TM) to his athletes for their post training nutritional needs. "SURGEX(TM) is a great adjunct to our training protocol and is being extremely well received by the players in camp this year," said Coach Shaw.


SURGEX(TM) ( was created from Millennium's extensive experience providing advanced nutritional formulas to some of the most prestigious medical institutions throughout the United States The proprietary SURGEX(TM) formula intends to meet the growing demand of elite level professional and amateur athletes and their coaches looking for nutritional support in a marketplace dominated by products with no clinical proof of benefit, unsubstantiated claims, excess protein, stimulants, and banned substances.

In double blind placebo controlled trials at the Rutgers University Human Performance Lab SURGEX(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise by improving peak power outputs, lowering oxidative stress/inflammatory markers, reducing fatigue (poor energy recovery) and the breakdown of muscle (post exercise wasting), as well as the lessening of free radical production (oxidative stress). The formula meets NCAA guidelines for use by collegiate athletes and is certified by The Banned Substances Control Group (BSCG) to contain no banned substances.

About Millennium:

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also recently developed a Surgex(TM) sports nutrition formula, clinically proven to address the nutritional concerns of both professional and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC"). These statements have not been evaluated by the Food and Drug Administration. Resurgex(R), Resurgex Plus(R), Resurgex Select(R) and Surgex(TM) are not intended to diagnose, treat, cure, or prevent and disease.

SOURCE Millennium Biotechnologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime
2. Workforce Alliance Concludes Three-Year Biotech Training Program
3. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
4. Beaumont Technology Usability Center To Offer Training For Medical Technology Companies
5. CCMR gets $2.9M for training grad students in nanoscale science
6. CCMR gets $2.9M for training grad students in nanoscale science
7. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
8. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
9. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
10. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
11. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
Post Your Comments:
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
Breaking Biology Technology:
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
Breaking Biology News(10 mins):